DASATINIB ANHYDROUS

SynDRA canonical compound SYN0006381 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx
Primary target(s)	YES1
Mechanism of action	Tyrosine kinase inhibitor
Indication	acute lymphoblastic leukemia (ALL) \| chronic myeloid leukemia (CML)
Disease area	hematologic malignancy

All known targets

dasatinib
sprycel
spyrcel
BMS-354825
dasatinib hydrate
Dasatinib (anhydrous)
Dasatinib accord
Dasatinib accordpharma
Dasatinib
Sprycel (TN)
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
Dasatinib (USAN)
Dasatinib [USAN]
Dasatinib, BMS 354825
Dasatinibum
Sprycel
Spyrcel
BMS 354825
Dasatinib (BMS-354825)
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
anh. dasatinib
anhydrous dasatinib
dasatinib (anh.)
CHEMBL1421
X78UG0A0RN
CHEBI:49375
Dasatinib D8
NSC732517
NSC-732517
NSC-759877
NCGC00181129-01
5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-
dasatinibum
BMS-354825 HYDRATE
5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-